INSIDE-CANVASBiomarker and Pathogenesis Study in RFC1-ataxia

This study aims to better understand a condition called RFC1-ataxia, a type of late-onset neurodegenerative disorder. Researchers are focusing on how to measure the severity and progression of the disease by using various clinical rating scales. They are also looking for new biomarkers in the blood that could help diagnose or track the disease's progression. The study involves RFC1-ataxia patients and healthy individuals to identify unique patterns or indicators in the disease. By examining the role of mitochondrial function in the development of RFC1-ataxia, the research hopes to uncover insights that could lead to better diagnosis and treatment options for those affected by this condition. Participants in the study will undergo various tests to gather data about their condition. This includes clinical assessments, blood tests, and imaging studies. Blood samples from participants will be analyzed for biomarkers that are linked to oxidative stress and neurodegeneration. Additionally, scientists will study cells from patients to examine mitochondrial function and see if any abnormalities are present. The data collected will be analyzed to see if there are any significant differences between RFC1-ataxia patients and healthy individuals, which could help identify biomarkers or targets for future treatments. The study's findings may potentially lead to new ways to track and treat RFC1-ataxia, improving the lives of those with the condition.